Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function

[1]  K. Sugimoto,et al.  Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. , 1989, British journal of clinical pharmacology.

[2]  G. Yasuda,et al.  Antihypertensive effect of delapril during long-term treatment in hypertensive patients , 1989 .

[3]  Y. Kaneko,et al.  Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. , 1988, Journal of cardiovascular pharmacology.

[4]  Y. Kaneko,et al.  Active and inactive plasma renin in hypertensive diabetics with or without nephropathy , 1988 .

[5]  G. Yasuda,et al.  Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure. , 1987, Clinical nephrology.

[6]  G. Yasuda,et al.  Pharmacokinetics and depressor effect of delapril in patients with essential hypertension , 1987, Clinical pharmacology and therapeutics.

[7]  Y. Oka,et al.  Design and synthesis of N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L -alanyl]-N-(indan-2-yl)glycine (CV-3317), a new, potent angiotensin converting enzyme inhibitor. , 1986, Chemical & pharmaceutical bulletin.

[8]  Y. Kaneko,et al.  Pharmacodynamics and pharmacokinetics of single-dose ramipril in hypertensive patients with various degrees of renal function , 1986 .

[9]  M. Yasumatsu,et al.  Determination of a new angiotensin converting enzyme inhibitor (CV-3317) and its metabolites in serum and urine by high-performance liquid chromatography. , 1985, Fukuoka igaku zasshi = Hukuoka acta medica.

[10]  G. Yasuda,et al.  Pharmacokinetics and antihypertensive effects of single and consecutive dosing of alacepril (DU-1219) in patients with severe hypertension , 1985 .

[11]  G. Yasuda,et al.  [Blood concentration and urinary excretion of captopril (SQ 14,255), angiotensin converting enzyme activity and R-A-A system after administration of captopril--in patients with chronic renal failure compared with essential hypertension]. , 1982, Nihon Jinzo Gakkai shi.

[12]  K. Iseki,et al.  Blood Concentration and Urinary Excretion of Captopril (SQ 14,225) in Patients with Chronic Renal Failure , 1981, Hypertension.

[13]  C. A. Stone,et al.  A new class of angiotensin-converting enzyme inhibitors , 1980, Nature.

[14]  R. Tarazi,et al.  Converting Enzyme Inhibition with an Orally Active Compound in Hypertensive Man , 1979, Hypertension.

[15]  B Rubin,et al.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. , 1977, Science.

[16]  G. Kolata.  Mathematician paul erdos: total devotion to the subject. , 1977, Science.

[17]  D W Cushman,et al.  Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. , 1971, Biochemical pharmacology.